January 24, 2017 -- Beijing Mabworks Biotech, a gene engineering mAb company, raised $39 million for a Series B round, led by Shenzhen GTJA Investment Group. GTJA is a healthcare focused investment firm. Founded in 2003, Mabworks is working on ZMapp, an Ebola treatment developed by San Diego’s MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech’s Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.
